Tevogen plans to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to accelerate the development of TVGN 489, a precision T cell therapy for COVID-19 and Long COVID. The Company’s clinical trial of TVGN 489 showed a favorable safety profile and valuable insights. Tevogen is preparing for the next stage of development and aims to maximize patient access once regulatory pathways allow. A dedicated communication channel for Long COVID updates has been established at [email protected]. Tevogen remains focused on sustainable advancement towards commercialization.

Read more at GlobeNewswire: Tevogen Updates on TVGN 489 Following Growing Long COVID